Show simple item record

dc.contributor.authorHanks, S
dc.contributor.authorPerdeaux, ER
dc.contributor.authorSeal, S
dc.contributor.authorRuark, E
dc.contributor.authorMahamdallie, SS
dc.contributor.authorMurray, A
dc.contributor.authorRamsay, E
dc.contributor.authorDel Vecchio Duarte, S
dc.contributor.authorZachariou, A
dc.contributor.authorde Souza, B
dc.contributor.authorWarren-Perry, M
dc.contributor.authorElliott, A
dc.contributor.authorDavidson, A
dc.contributor.authorPrice, H
dc.contributor.authorStiller, C
dc.contributor.authorPritchard-Jones, K
dc.contributor.authorRahman, N
dc.date.accessioned2020-08-13T11:48:08Z
dc.date.issued2014-08-07
dc.identifier.citationNature communications, 2014, 5 pp. 4398 - ?
dc.identifier.issn2041-1723
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3956
dc.identifier.eissn2041-1723
dc.identifier.doi10.1038/ncomms5398
dc.description.abstractWilms tumour is a childhood kidney cancer. Here we identify inactivating CTR9 mutations in 3 of 35 Wilms tumour families, through exome and Sanger sequencing. By contrast, no similar mutations are present in 1,000 population controls (P<0.0001). Each mutation segregates with Wilms tumour in the family and a second mutational event is present in available tumours. CTR9 is a key component of the polymerase-associated factor 1 complex which has multiple roles in RNA polymerase II regulation and is implicated in embryonic organogenesis and maintenance of embryonic stem cell pluripotency. These data establish CTR9 as a Wilms tumour predisposition gene and suggest it acts as a tumour suppressor gene.
dc.formatElectronic
dc.format.extent4398 - ?
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectKidney
dc.subjectLymphocytes
dc.subjectHumans
dc.subjectGenetic Predisposition to Disease
dc.subjectNuclear Proteins
dc.subjectPhosphoproteins
dc.subjectTranscription Factors
dc.subjectPedigree
dc.subjectDNA Mutational Analysis
dc.subjectAlternative Splicing
dc.subjectHeterozygote
dc.subjectGerm-Line Mutation
dc.subjectExons
dc.subjectChild, Preschool
dc.subjectInfant
dc.subjectFamily Health
dc.subjectFemale
dc.subjectMale
dc.subjectWilms Tumor
dc.subjectExome
dc.titleGermline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour.
dc.typeJournal Article
dcterms.dateAccepted2014-06-13
rioxxterms.versionofrecord10.1038/ncomms5398
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.licenseref.startdate2014-08-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature communications
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Genetic Susceptibility
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Genetic Susceptibility
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Genetic Susceptibility
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Genetic Susceptibility
pubs.publication-statusPublished
pubs.volume5
pubs.embargo.termsNot known
icr.researchteamMedicine Drug Development Unit (de Bono)
icr.researchteamGenetic Susceptibility
dc.contributor.icrauthorZachariou, Anna
dc.contributor.icrauthorElliott, Anna


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0